European Environmental Mutagen Society Research Articles

Abstracts of the 43rd Annual Meeting of the European Environmental Mutagen Society Lancaster University UK 6–10 July 2014

Abstracts of the 43rd Annual Meeting of the European Environmental Mutagen Society Lancaster University UK 6–10 July 2014

Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part IV:Recommendation of a Working Group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a Simple and Straightforward Approach to Genotoxicity Testing

Based on new scientific developments and experience of the regulation of chemical compounds, a working group of the Gesellschaft fuer Umweltmutationsforschung (GUM), a German-speaking section of the European Environmental Mutagen Society, proposes a simple and straightforward approach to genotoxicity testing. This strategy is divided into basic testing (stage I) and follow-up testing (stage II). Stage I consists of a bacterial gene mutation test plus an in vitro micronucleus test, therewith covering all mutagenicity endpoints. Stage II testing is in general required only if relevant positive results occur in stage I testing and will usually be in vivo. However, an isolated positive bacterial gene mutation test in stage I can be followed up with a gene mutation assay in mammalian cells. If this assay turns out negative and there are no compound-specific reasons for concern, in vivo follow-up testing may not be required. In those cases where in vivo testing is indicated, a single study combining the analysis of micronuclei in bone marrow with the comet assay in appropriately selected tissues is suggested. Negative results for both end points in relevant tissues will generally provide sufficient evidence to conclude that the test compound is nongenotoxic in vivo. Compounds which were recognized as in vivo somatic cell mutagens/genotoxicants in this hazard identification step will need further testing. In the absence of additional data, such compounds will have to be assumed to be potential genotoxic carcinogens and potential germ cell mutagens.

Change of Venue: Taking Environmental Mutagen Research to the Developing World

The health of a nation could be said to depend upon the public health expertise of its scientists. In the United States and other developed areas of the world, it can be fairly simple to gain access to a variety of useful public health resources. But populations living in less-developed areas of the world often lack such knowledge and public health access. In 1987, two young scientists, William Au of the University of Texas Medical Branch (UTMB) and Wagida Anwar of Ain Shams University in Cairo, Egypt, decided to seek ways to raise the level of access to information and technical expertise regarding environmental health disparities in less-developed regions. With a main goal of encouraging collaborations for growth of scientific knowledge and expertise as well as clinical applications in underserved areas, they focused on organizing an international conference highlighting the latest research and information on environmental mutagens. The fruit of that labor, the International Conference on Environmental Mutagens in Human Populations (ICEMHP) series, has become a boon to the scientific community in developing nations. The next conference, sponsored in part by the NIEHS, is scheduled for May 2007 in Antalya, Turkey. NIEHS scientist Mike Waters, chairman of the ICEMHP International Advisory Board, says the institute has been a key participant in the conference series since its inception, noting that institute scientists have helped with organizing activities, and that NIEHS leaders have contributed personal and financial support. He also points out that the proceedings of the first two conferences were published in the October 1993 and May 1996 issues of EHP Supplements. According to Waters, the mission of the NIEHS lends itself to sponsorship of the ICEMHP series. “[The NIEHS] fosters national as well as international efforts to reduce the burden of environmentally associated disease,” he explains. “This series of conferences certainly has the same objective. It represents an effective means of communicating and extending the NIEHS mission and its research findings to the developing world.” Other past and current sponsors for the conference series include the U.S. CDC, Novartis Pharmaceutical Company, the U.S. Environmental Mutagen Society, the European Environmental Mutagen Society, the International Association of Environmental Mutagen Societies, the Turkish Society of Toxicology, Research Corporation, and the UTMB Department of Preventive Medicine and Community Health and Sealy Center for Environmental Health and Medicine.

SFTG international collaborative study on in vitro micronucleus test: I. General conditions and overall conclusions of the study

This study, coordinated by the SFTG (French branch of European Environmental Mutagen Society), included 38 participants from Europe, Japan and America. Clastogens (bleomycin, urethane), including base and nucleoside analogs (5-fluorouracil and cytosine arabinoside), aneugens and/or polyploidy inducers (colchicine, diethylstilboestrol, griseofulvin and thiabendazole), as well as non-genotoxic compounds (mannitol and clofibrate), were tested. Four cell types were used, i.e. human lymphocytes in the presence of cytochalasin B and CHO, CHL and L5178Y cell lines, in the presence or absence of cytochalasin B, with various treatment-recovery schedules. Mitomycin C was used as a positive control for all cell types. Mannitol and clofibrate were consistently negative in all cell types and with all treatment-recovery conditions. Urethane, known to induce questionable clastogenicity, was not found as positive. Bleomycin and mitomycin C were found positive in all treatment-recovery conditions. The base and nucleoside analogs were less easy to detect, especially 5-fluorouracil due to the interference with cytotoxicity, while cytosine arabinoside was detected in all cell types depending on the treatment-recovery schedule. Aneugens (colchicine, diethylstilboestrol and griseofulvin) were all detected in all cell types. In this study, the optimal detection was ensured when a short treatment followed by a long recovery was associated with a long continuous treatment without recovery. There was no impact of the presence or absence of cytochalasin B on the detection of micronucleated cells on cell lines. Scoring micronucleated cells in both mononucleated and binucleated cells when using cytochalasin B was confirmed to be useful for the detection and the identification of aneugens. In conclusion, these results, together with previously published validation studies, provide a useful contribution to the optimisation of a study protocol for the detection of both clastogens and aneugens in the in vitro micronucleus test.

SFTG international collaborative study on in vitro micronucleus test: III. Using CHO cells

In this report, results are presented from an international study of the in vitro micronucleus assay using Chinese hamster ovary cells. This study was coordinated by an organizing committee supported by the SFTG (the French branch of the European Environmental Mutagen Society). Test chemicals included mannitol, bleomycin, cytosine arabinoside, urethane and diethylstilboestrol. Mitomycin C was used as a positive control. Each chemical was evaluated in at least two laboratories following a variety of different protocols (short and long exposures, varying recovery times, with and without cytochalasin B) in order to help determine a standard protocol for routine testing in Chinese hamster ovary cells. Mannitol and urethane were negative, while bleomycin, cytosine arabinoside and diethylstilboestrol induced a dose dependent increase in micronucleated cells. In the presence of cytochalasin B, increases in micronuclei were observed in binucleated as well as mononucleated cells in cultures treated with bleomycin, cytosine arabinoside or diethylstilboestrol. Importantly, all three of these chemicals were detected in each of the different treatment/recovery regimens. No differences were seen in the sensitivity or accuracy of the responses in the presence of absence of cytochalasin B. Overall, these results demonstrate the suitability of Chinese hamster ovary cells for the in vitro micronucleus assay.

SFTG international collaborative study on in vitro micronucleus test: V. Using L5178Y cells

In this report, results are presented from an international study of the in vitro micronucleus assay using mouse lymphoma L5178Y cells. This study was coordinated by an organizing committee supported by the SFTG (the French branch of the European Environmental Mutagen Society). Test chemicals included mannitol, bleomycin, 5-fluorouracil, colchicine and griseofulvin. Mitomycin C was used as a positive control. Each chemical was evaluated in at least two laboratories following a variety of different protocols (short and long exposures, varying recovery times, with and without cytochalasin B) in order to help determine a standard protocol for routine testing in mouse lymphoma L5178Y cells. Mannitol was the only exception, being tested in only one laboratory. Mannitol was negative, while bleomycin induced a concentration-dependent increase in micronucleated cells. Equivocal results were obtained for 5-fluorouracil, colchicine and griseofulvin. High levels of cytotoxicity interfered with the assessment of aneuploidy for colchicine and griseofulvin, preventing the ability to obtain clear results in all the treatment schedules. Experiments with 5-fluorouracil, colchicine and griseofulvin showed that both short and long treatment times are required as each compound was detected using one or more treatment protocol. No clear differences were seen in the sensitivity or accuracy of the responses in the presence of absence of cytochalasin B. It was also found that a recovery period may help to detect compounds which induce a genotoxicity associated to a reduction in cell number or cell proliferation. Overall, the results of the present study show that mouse lymphoma L5178Y cells are suitable for the in vitro micronucleus assay.

SFTG international collaborative study on in vitro micronucleus test: IV. Using CHL cells

In this report, are presented the results of an international collaborative study on the in vitro micronucleus assay, using CHL cells. Fourteen laboratories participated in this study which was coordinated by an organizing committee supported by the SFTG (the French branch of the European Environmental Mutagen Society). Nine coded substances, having different modes of action and at different levels were assessed in the in vitro micronucleus test, using a common protocol. Mitomycin C was used as a positive control. In order to help to define a standard protocol on CHL cells, short and long treatment periods followed by various recovery times, with or without cytochalasin B, were compared. After an evaluation of the acceptability of the assays, the tested chemicals were classified as negative, positive or equivocal. Mannitol and clofibrate were judged as negative in all treatment schedules. Bleomycin was positive in all the treatment schedules, with an increase in the number of micronucleated cells in both mononucleate and binucleate cells when using cytochalasin B. This was also shown for the aneugens colchicine, diethylstilboestrol and griseofulvin, as expected. Urethane was judged as equivocal only after long treatment with cytochalasin B, and negative in all other treatment schedules. In any case, no genotoxic compound would have been missed with schedules including a short and a long treatment time, whether the treatment was followed by a recovery period or not and whether cytochalasin B was used or not. Thus, these results show that CHL cells were suitable for accurately detecting clastogenic and aneugenic compounds of various types in the in vitro micronucleus test.

SFTG international collaborative study on in vitro micronucleus test: II. Using human lymphocytes

This study on the in vitro micronucleus assay, comprising 11 laboratories using human lymphocytes, was coordinated by an organizing committee supported by the SFTG (the French branch of the European Environmental Mutagen Society). Nine coded substances were assessed for their ability to induce micronuclei in human lymphocytes in vitro, mitomycin C being used as a positive control. Cultures were exposed to the test substances for a short (early or late) time or for a long time, followed by a short or long recovery period, in the presence of cytochalasin B. Each chemical was evaluated, generally in two laboratories, using three treatment schedules at least twice. The data were assessed for acceptability, and then classified as negative, positive or equivocal. Two of seven genotoxic compounds, namely colchicine and bleomycin, clearly induced micronuclei. Reproducible results were difficult to obtain for some substances, which tended to be those acting at specific stages of the cell cycle. Cytosine arabinoside, diethylstilboestrol and 5-fluorouracil were classified as equivocal. Urethane and thiabendazole were classified as negative. The two presumed non-genotoxic compounds, mannitol and clofibrate, did not induce micronuclei. Repeat testing, exposing cells at both an early and late time after mitogenic stimulation, was needed to detect substances classified as equivocal. These results show the importance of achieving sufficient inhibition of nuclear division to avoid the possibility of missing an effect. The evaluation of micronuclei in mononucleated as well as binucleated cells was particularly useful to detect aneugens. There were no false positive results using lymphocytes, indicating a high specificity. It is concluded that the clastogenic or aneugenic potential in vitro of the substances tested was correctly identified in this study, but that refining the protocol to take into account factors such as the stages of the cell cycle exposed to the compound, or the duration of recovery would be likely to improve the sensitivity of detection using lymphocytes.

Abstracts from EEMS‐99 2gth Annual Meeting of the European Environmental Mutagen Society: 4‐9 July, 1999

Pharmacology & ToxicologyVolume 85, Issue 1 p. 1-76 Free Access Abstracts from EEMS-99 2gth Annual Meeting of the European Environmental Mutagen Society: 4-9 July, 1999 First published: 25 March 2009 https://doi.org/10.1111/j.1600-0773.1999.tb01705.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume85, Issue1July 1999Pages 1-76 RelatedInformation

First annual meeting of the Italian Section of the European Environmental Mutagen Society (SIMA)

First annual meeting of the Italian Section of the European Environmental Mutagen Society (SIMA)

Selected Abstracts presented by UKEMS Members at the 20th Annual Meeting of the European Environmental Mutagen Society, July 22–27, 1990, University of York, UK

Selected Abstracts presented by UKEMS Members at the 20th Annual Meeting of the European Environmental Mutagen Society, July 22–27, 1990, University of York, UK

Twentieth European Environmental Mutagen Society (EEMS) meeting: July 22–27, 1990 York, U.K.

Twentieth European Environmental Mutagen Society (EEMS) meeting: July 22–27, 1990 York, U.K.

20th European environmental mutagen society (EEMS) meeting: 22–27 July 1990, York (Great Britain)

20th European environmental mutagen society (EEMS) meeting: 22–27 July 1990, York (Great Britain)

Gesellschaft für Umwelt-Mutationsforschung e.V. (GUM) A German-speaking section of the European Environmental Mutagen Society (EEMS) Abstracts of papers presented at the 11th meeting October 12–14, 1988, Mainz, FRG

Gesellschaft für Umwelt-Mutationsforschung e.V. (GUM) A German-speaking section of the European Environmental Mutagen Society (EEMS) Abstracts of papers presented at the 11th meeting October 12–14, 1988, Mainz, FRG

XVII Annual Meeting of the European Environmental Mutagen Society

Journal Article XVII Annual Meeting of the European Environmental Mutagen Society Get access Susan A. Hubbard Susan A. Hubbard Search for other works by this author on: Oxford Academic PubMed Google Scholar Mutagenesis, Volume 3, Issue 2, March 1988, Page 175, https://doi.org/10.1093/mutage/3.2.175 Published: 01 March 1988

EEMS — European environmental mutagen society, XVIIth annual meeting: Zürich, 19–23 July 1987

EEMS — European environmental mutagen society, XVIIth annual meeting: Zürich, 19–23 July 1987

EEMS — European Environmental Mutagen Society, XVIIth Annual Meeting: Zürich, 19–23 July 1987

EEMS — European Environmental Mutagen Society, XVIIth Annual Meeting: Zürich, 19–23 July 1987

EEMS - European Environmental Mutagen Society, XVIIth annual meeting: Zürich, 19–23 July 1987

EEMS - European Environmental Mutagen Society, XVIIth annual meeting: Zürich, 19–23 July 1987

EEMS: 12th annual meeting of the European Environmental Mutagen Society Dipoli, Espoo, Finland, 20–24 June 1982

EEMS: 12th annual meeting of the European Environmental Mutagen Society Dipoli, Espoo, Finland, 20–24 June 1982

11th Annual meeting of the European environmental mutagen society

11th Annual meeting of the European environmental mutagen society